Iran is pushing boundaries amid rising tensions in the Gulf, but President Trump has so far not been "compelled" to retaliate militarily, analysts say.World Politicsread more
The U.K. will find out who its next prime minister will be on Tuesday.Europe Politicsread more
UBS announced a net profit of $1.4 billion for the second quarter of 2019.Earningsread more
Japan and South Korea are part of a complex and tightly linked supply chain that produces electronic goods such as smartphones and laptops.Technologyread more
Michael Kugelman from the U.S.-based Wilson Center says other issues take precedence in the bilateral dialogue between the United States and Pakistan — namely, Afghanistan and...Asia Politicsread more
Beijing says it can still meet its 2019 growth target of between 6% and 6.5% and continues to roll out stimulus measures to prop up activity. China set a 2019 industrial...China Economyread more
A different oil pricing dynamic has been evolving with new supply calculations based on the U.S. as the world's largest producer.Market Insiderread more
The Massachusetts senator's alarm-sounding on consumer debt neglects to measure it against the growth in the economy and the ability to pay.Economyread more
Stocks in Asia Pacific edged up on Tuesday, as investors await closely-watched central bank meetings in the coming days.Asia Marketsread more
More than half of Venezuela's 23 states lost power on Monday, according to Reuters witnesses and reports on social media, a blackout the government blamed on an...World Politicsread more
Equifax will give consumers a range of options for monitoring their credit or making claims of fraud or data misuse, part of a $425 million restitution fund.Technologyread more
Biogen's offer of $25.50 per share, represents a premium of 68 percent to Nightstar's Friday close of $15.16.
Gene therapy, an emerging field of biotechnology, uses specially engineered viruses, or viral vectors, to deliver genetic material into defective cells, in hopes of improving or potentially even curing an inherited condition.
London-based gene therapy company Nightstar is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
"Ophthalmology is an emerging growth area for Biogen," said Michel Vounatsos, Biogen's chief executive officer. "Nightstar would accelerate our entry into ophthalmology by contributing two mid- to late-stage gene therapy assets."
Biogen said it plans to fund the acquisition through available cash.
Last week, Sarepta Therapeutics Inc beefed up its gene therapy portfolio through the purchase of its partner Myonexus Therapeutics, while Swiss drugmaker Roche said it was buying U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion.
Goldman, Sachs is acting as financial adviser to Biogen and Centerview Partners was Nightstar's financial adviser.